Co-Diagnostics Q3 2023 Gaap EPS $(0.20) Beats $(0.29) Estimate, Sales $2.46M Beat $200.00K Estimate
Portfolio Pulse from saritha@benzinga.com
Co-Diagnostics (NASDAQ:CODX) reported Q3 2023 GAAP EPS of $(0.20), beating the analyst consensus estimate of $(0.29) by 31.03%. The company also reported quarterly sales of $2.46M, surpassing the analyst consensus estimate of $200.00K by 1.13K%. However, these figures represent a decrease from the same period last year.
November 09, 2023 | 9:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Co-Diagnostics' Q3 2023 results exceeded analyst estimates, which could positively impact investor sentiment. However, the decrease from last year's figures may temper this effect.
Co-Diagnostics' better-than-expected Q3 2023 results could boost investor confidence and potentially lead to a short-term increase in the stock price. However, the year-over-year decrease in both EPS and sales might offset this positive effect, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100